Arcellx, Inc.

ACLX

Biological Products, (No Diagnostic Substances)

Mkt Cap

$2.706B

PE

-53.55

Debt

Cash

$157.2M

EV

FCF

-$33.26M

Market Cap

$2.706B

P/E Ratio

-53.55

Debt

Cash

$157.2M

EV

FCF

-$33.26M

Charts data: {"Earnings":[{"time":"2021-12-30","value":-64969000},{"time":"2022-12-30","value":-188679000},{"time":"2023-12-30","value":-70690000}],"Sales":[{"time":"2023-12-30","value":110319000}],"Net Margins":[{"time":"2023-12-30","value":-0.6407781071256992}],"Assets":[{"time":"2021-12-30","value":128782000},{"time":"2022-12-30","value":313817000},{"time":"2023-12-30","value":825132000}],"Stockholders Equity":[{"time":"2021-12-30","value":-121515000},{"time":"2022-12-30","value":204954000},{"time":"2023-12-30","value":485380000}],"ROE":[{"time":"2021-12-30","value":0.5346582726412377},{"time":"2022-12-30","value":-0.9205919377030943},{"time":"2023-12-30","value":-0.1456384688285467}],"ROA":[{"time":"2021-12-30","value":-0.5048686928297433},{"time":"2022-12-30","value":-0.6012389386170921},{"time":"2023-12-30","value":-0.08486763329988414}]}

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Over time the ROA has been increasing indicating a higher marginal ROA with respect to the calculated one, giving a good sign for continued growth.

Years	12-2021	12-2022	12-2023	TTM
Net Margin	-	-	-64%	-38%
ROA	-50%	-60%	-8.5%	-6.4%
ROE	53%	-92%	-15%	-10%

What is the average Net Margin?

The average Net Margin over the past 5 years is -64.08%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -39.7%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +21%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -17.72%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -34.01%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Data are missing

Years	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-	-	-
Debt Equity	-	-	-	-
MIN
Graham Stability	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2022	Trend
Revenue	-	-
Net Income	-	-
Stockholders Equity	140%	-
FCF	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.